Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology

Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC

Recorded on February 19, 2026

Matthew Kutny, MD
Professor of Pediatrics
Director, Leukemia, Lymphoma and Histiocytosis Program
Director, Pediatric Clinical Trials Office
Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN)
Pediatric Hematology and Oncology
University of Alabama at Birmingham
Birmingham, AL
Julie Guillot
Pediatric AML parent, global advocate, and Blood Cancer United Volunteer
Kelly Laschinger, MSN, RN, CPNP, CPHON
Director, Clinical Trial Support Center
Blood Cancer United
Washington, DC
In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access!

Blood Cancer United Resources:

• Clinical Trial Support Center
• Information Resource Center
• Dare to Dream Project
• Pediatric Acute Leukemia Master Clinical Trial (PedAL)

Mentioned on this episode:

• Project Facilitate

This episode is supported by the Tom Reich Educational Endowment Fund.